Skinbiotherapeutics Share Discussion Threads

[danatkins] 22/11/2018 17:38

No no ray no phase 123 it will be classed as a medical device which although has strict requirements it not the same. All this will come out in the wash at some point. As with everything there are risks and rewards for what works. Losers and winners. That's life

[riskybusiness1] 22/11/2018 16:42

The comprehensive studies have been designed so that the cosmetic studies go hand in hand with the pharmaceutical pathway. This significantly decreases the time taken to the pharma market on the back of early sales from a less stringent regulatory cosmetic market.Sound a bit familiar to how Optibiotix are building revenues with LPLDL in the supplement market whilst a US pharmaceutical takes it down a pharma route which is of course longer but brings an immense amount of value to the IP and revenues in a significantly higher valued market.

[manc10] 22/11/2018 16:02

lpldl is for cholesterol you thought it was a cream for eczema . you could not make it up how long have you been on bullsh"tbiome it defo works you mug

[rayrac] 22/11/2018 15:50

Lol! This is not a pharma...but the cream has a pharmaceutical action that cures eczema, or so they say. Takes some believing? The proof will be in the selling of it...or not.

[slartybartfaster] 22/11/2018 15:05

Silly senile fool.

[manc10] 22/11/2018 14:56

rayrat the man who said lpldl will not get rid of eczema lol . and told a inexperienced investor to sell sbtx and buy bpc the day later bpc fell 80% listen to this mug at your peril

[rayrac] 22/11/2018 14:34

Which will mean nothing. Unless you mean proper phase 1/2/3 tests? No? I thought not, all in house stuff!

[rathean] 22/11/2018 11:06

Plenty taking a position now before it creeps back up in anticipation of the final test results.

[rafboy] 22/11/2018 08:51

Bit of interest this morning, good to see.

[jammyjim] 21/11/2018 20:53

A Very interesting video .it Goes to show that the CEO of this company is a very switched on lady. There is lots to come from SBTX in the future and I am looking forward to watching it grow .

[slartybartfaster] 21/11/2018 18:54

This isn't a TW tip.

[manc10] 21/11/2018 14:42

a bit on our ceo

[rathean] 21/11/2018 10:45

Agreed, maybe even 12.5 but upside if the ducks align is substantial from here imo dyor ofc.

[matt123d] 21/11/2018 10:26

Heading for 13/14 by the look of it.

[rathean] 21/11/2018 08:21

Happy to be back in after a long time watching, same with OPTI. Tucking them both away until the relief rally or rns driven rise :)

[michaelmouse] 20/11/2018 17:44

post 313 #graspingatstraws #uselessanalogy #overvaluednonrevenuerubbish

[riskybusiness1] 20/11/2018 17:24

The USP is the scientifically validated studies. It's the cutting edge science which is where IP holds so much of its value. Therein lies your problem which you continue to ignore. If industry thought like you the entire human race would never develop anything. Your view would have the digital camera inventors saying there's no point because there's the Kodak to take pictures and consumers won't know the difference.Are you going to actively look for and buy a product that has been scientifically validated or one that has questionable data because of old science? BTW there has been a huge shift in consumer education in the probiotic space encouraging consumers to look for validated science. (This is why there is rapid growth in microbiome space) If your too busy deceiving to see it that way then think of industry. They'll be tasked with looking for the next big technological advancement to that space and marketing it to consumers.

[michaelmouse] 20/11/2018 16:59

post 311 - "Just because the microbiome is used in the same sentence does not mean they are in any way similar in terms of what they offer."

Therein lies your massive problem. If nobody understands the difference then where is the USP. It's a huge problem for OPTI and SBTX. When these products hit the market, consumers won't have a clue, they'll be so many claiming #metoo microbiome. Any USP you think you've got will be lost in the noise. Product sales won't gain traction, and clients won't re-order. #you'reverynaive #marketisalreadyovercrowded #goingdownthepan

Aimho of course.

[riskybusiness1] 20/11/2018 16:02

Oh look it's michaelmouse looking to deceive. Comparing Intugumen (SKIN) with SBTX just shows how little you know about this space.Intugumen have been around for a long time and have nothing in terms of valuable IP. Just because the microbiome is used in the same sentence does not mean they are in any way similar in terms of what they offer.

[manc10] 20/11/2018 14:29

as kath oneil says sbtx has loads of money in the bank

[michaelmouse] 20/11/2018 14:25

Interesting comparison with SKIN:-



"Balanced Microbiome Labskin Certified:
Confirmation of Labskin test results showing a balanced microbiome that contributes a positive outcome to skin treatment can now be certified for our clients' cosmetic and skin care products."

Except SKIN is actually making revenues and valued at just £1.5m, whereas SBTX is making no revenues and valued at £19m.

Not interested in either. I fully expect SBTX to be less than 1p in the fullness of time.

[manc10] 20/11/2018 14:19

mr trakm8 is back lol

[rathean] 20/11/2018 14:07

You just sound lonely ;)This is not pharma, it's a marketable brand with some skincare benefits with no adverse reactions unless you wear tube after tube of it... and assuming these final trials come in positive.Imo the share price could easily test 50p on successful completion of this trial given their pre-commercisation already in place.All IMHO ofc, dyor or just sit in your PJs whining at your laptop screen... up to you.

[michaelmouse] 20/11/2018 13:31

I think you'll find it's a pointless RNS which regurgitates everything you already know except the fact that the first human study demonstrated that their "quackery" does SFA.

The RNS is a desperate attempt to prop up the price of an massively overvalued company with zero revenues in a bear market.

Even a whiff that results are not as good as hoped and the share price will rapidly sink below a penny.

[riskybusiness1] 20/11/2018 10:16

RNS highlights the main development risks have been ticked off. Eg manufacture scale up, freeze dry stability and safety. All there is now is efficacy which has already been proven in laboratory and can be played with in terms of dosage. Positioned really nicely now.